18+ · Research Use Only · Not for Human Consumption
Tirzepatide vs semaglutide: the head-to-head is over.
SURMOUNT-5 answered the question the field argued about for years. Here is what the data says, and what each compound costs from a Philippine vantage point.
What SURMOUNT-5 settled
For years the comparison ran on indirect evidence. Semaglutide's STEP 1 (NEJM 2021) reported 14.9% mean weight reduction at 68 weeks. Tirzepatide's SURMOUNT-1 (NEJM 2022) reported 22.5% at 72 weeks. Bigger number, but different trials, so the debate continued. SURMOUNT-5 ended it by running the two compounds against each other directly, and the result favored tirzepatide. The dual GIP and GLP-1 mechanism outperformed the single GLP-1 mechanism in the same trial, on the same protocol, in the same population.
For research purposes that head-to-head matters more than any cross-trial comparison. It is the cleanest published evidence that adding GIP receptor activity to a GLP-1 backbone changes the outcome, and it is the reason the field kept moving toward multi-receptor designs like retatrutide, covered in the retatrutide comparison.
The local availability picture
In the Philippines the two compounds live in different markets. Semaglutide is a prescription pharmaceutical: Ozempic pens through hospital and retail pharmacies, prescription required, monthly costs that run to five figures in pesos. There is no research-vial semaglutide in the Primara Labs catalogue.
Tirzepatide exists on both sides. Mounjaro is the pharmacy product, and research-grade tirzepatide ships as a 10mg lyophilized vial at ₱2,500, or ₱2,250 on a first order. The tirzepatide product page shows live stock; vials are in stock and dispatch same day across Metro Manila on verified orders.
What this means for a research buyer
If the research question is about the best-documented incretin, semaglutide keeps that title on sheer volume of human data, but it is only reachable through the pharmacy channel here. If the question is about the stronger published outcome, SURMOUNT-5 gives that to tirzepatide, and the research vial route prices it at a fraction of pen cost. And if the question is about where the field is heading, the answer is already past both: triple-agonist work has moved to retatrutide, which is in stock now at ₱2,510 on a first order. Whichever way the work points, orders verified before noon dispatch same day across Metro Manila, with insulated courier nationwide in 1 to 3 days.
Supplied for laboratory research use only. Not for human consumption. Nothing on this page is medical advice.
Tirzepatide vs semaglutide questions
Which performed better in trials, tirzepatide or semaglutide?
SURMOUNT-5, the direct head-to-head trial, favored tirzepatide over semaglutide. Before that, tirzepatide reported 22.5% mean weight reduction at 72 weeks in SURMOUNT-1 (NEJM 2022) against semaglutide's 14.9% at 68 weeks in STEP 1 (NEJM 2021).
How much is tirzepatide in the Philippines as a research compound?
Tirzepatide 10mg lists at ₱2,500 at Primara Labs, or ₱2,250 on a first order with the 10% discount.
Is semaglutide available as a research vial from Primara Labs?
No. Semaglutide in the Philippines is a prescription pharmaceutical sold in pen form through pharmacies. The Primara Labs catalogue carries tirzepatide and retatrutide as its incretin research compounds.
What is the mechanistic difference between the two compounds?
Semaglutide activates one receptor, GLP-1. Tirzepatide activates two, GIP and GLP-1. The added GIP activity is the leading explanation in the literature for the difference in trial outcomes.